Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Internatl. drug schedulinq

Executive Summary

FDA announced in the Sept. 6 Federal Register that a public meeting will be held Oct. 10 at 8:30 am at the agency's Parklawn Bldg. for consideration of the World Health Organization's proposals on internatl. manufacturing and distribution restrictions for certain stimulant and/or hailucinogenic drugs. Agency noted that the Commission on Narcotic Drugs has decided to include dimethoxybromoamphetamine and methylenedioxyamphetamine in Schedule I. The World Health Organization has recommended that 17 stimulant and/or hailucinogenic drug substances be controlled.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel